Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

LENZ Therapeutics, Inc. - Common Stock (NQ:LENZ)

5.660 -0.160 (-2.75%)

Streaming Delayed Price Updated: 1:00 PM EDT, Jun 29, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	247,049
Open	5.840
Bid (Size)	5.650 (300)
Ask (Size)	5.670 (200)
Prev. Close	5.820
Today's Range	5.520 - 5.850
52wk Range	5.230 - 50.40
Shares Outstanding	58,102,949
Dividend Yield	254.77%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

June 24, 2026

Exclusive license and commercialization agreement includes a significant profit share of gross margin from product sales in addition to an upfront license payment to LENZ

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

June 07, 2026

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Performance

YTD	-64.6%	-64.6%
1 Month	-27.2%	-27.2%
3 Month	-31.7%	-31.7%
6 Month	-65.7%	-65.7%
1 Year	-80.7%	-80.7%

More News

Alpha Wave Global Reduces RadNet Stake, According to Recent SEC Filing ↗

June 02, 2026

Via The Motley Fool

LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock ↗

May 11, 2026

Via Chartmill

LENZ Therapeutics Inc (NASDAQ:LENZ) Reports Q4 Revenue Miss and Wider Loss Following VIZZ Launch ↗

March 24, 2026

Via Chartmill

Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing ↗

May 27, 2026

Via The Motley Fool

LENZ Therapeutics to Participate in Upcoming Investor Conferences

May 26, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Q1 Earnings Call Highlights ↗

May 11, 2026

Via MarketBeat

Lenz (LENZ) Q1 2026 Earnings Call Transcript ↗

May 11, 2026

Via The Motley Fool

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 11, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

April 20, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Why Lenz Therapeutics Stock Plummeted by Almost 20% This Week ↗

March 27, 2026

Via The Motley Fool

Why Lenz Therapeutics Stock Crashed Today ↗

March 24, 2026

Via The Motley Fool

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

March 24, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

Top Wall Street Forecasters Revamp LENZ Therapeutics Expectations Ahead Of Q4 Earnings ↗

March 23, 2026

Via Benzinga

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

March 17, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

March 10, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

LENZ Therapeutics to Present at Upcoming Investor Conferences

February 23, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 20, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

January 14, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 13, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

January 07, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

January 06, 2026

From Pomerantz LLP

Via GlobeNewswire

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

January 05, 2026

From LENZ Therapeutics, Inc.

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc. - LENZ

December 30, 2025

From Pomerantz LLP

Via GlobeNewswire

Frequently Asked Questions

Is LENZ Therapeutics, Inc. - Common Stock publicly traded?

Yes, LENZ Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does LENZ Therapeutics, Inc. - Common Stock trade on?

LENZ Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for LENZ Therapeutics, Inc. - Common Stock?

The ticker symbol for LENZ Therapeutics, Inc. - Common Stock is LENZ on the Nasdaq Stock Market

What is the current price of LENZ Therapeutics, Inc. - Common Stock?

The current price of LENZ Therapeutics, Inc. - Common Stock is 5.660

When was LENZ Therapeutics, Inc. - Common Stock last traded?

The last trade of LENZ Therapeutics, Inc. - Common Stock was at 06/29/26 01:00 PM ET

What is the market capitalization of LENZ Therapeutics, Inc. - Common Stock?

The market capitalization of LENZ Therapeutics, Inc. - Common Stock is 328.86M

How many shares of LENZ Therapeutics, Inc. - Common Stock are outstanding?

LENZ Therapeutics, Inc. - Common Stock has 329M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.